About: http://data.cimple.eu/news-article/53749cc47a74b7f02b2121d84a9df307dfe513f99c6a6d400adabe1b     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : schema:NewsArticle, within Data Space : data.cimple.eu associated with source document(s)

AttributesValues
rdf:type
schema:articleBody
  • Novartis announced Thursday it will join forces with fellow Swiss pharmaceutical giant Roche to produce tocilizumab, a drug being tested for its effectiveness against Covid-19-linked pneumonia. It is the third time Novartis has made its production capacities available to a competitor during the coronavirus pandemic, as several laboratories strike unprecedented partnerships to fight the global crisis. Novartis is already collaborating with BioNTech and CureVac in producing Covid-19 vaccines. The new tocilizumab deal will see Roche's manufacturing expertise transferred to the Novartis Drug Substance Singapore production site during the second quarter of 2021. "Novartis is fully committed to collaborating with Roche in offering our proven biologics production capabilities," said Steffen Lang, the firm's technical operations chief. "As one of the world's largest producers of medicines, Novartis can mobilise its manufacturing capabilities on multiple fronts." Sold as Actemra or RoActemra depending on the market, tocilizumab is a treatment for rheumatoid arthritis which is also being tested in clinical trials investigating its safety and efficacy against Covid-19-associated pneumonia. The injected treatment has suffered several setbacks in clinical trials. However, a large British study published in February reported encouraging results, particularly in reducing the risk of death. In January, Novartis announced an agreement with Pfizer-BioNTech to provide manufacturing capacity for its Covid-19 jabs. In March, it then struck an agreement to manufacture the mRNA and bulk drug product for CureVac's Covid-19 candidate vaccine. Faced with the desperate shortage of vaccine production capacity in dealing with the pandemic, unprecedented cooperation has been struck between laboratories. Novartis did not join the race to produce a Covid-19 jab, being no longer involved in vaccines following a major reorganisation in 2015. Its vaccines were sold to the British firm GlaxoSmithKline, with the exception of its influenza jabs which were sold off separately to the Australian laboratory CSL. noo/rjm/nl/wai
schema:headline
  • Novartis, Roche team up on Covid pneumonia drug
schema:mentions
schema:author
schema:datePublished
http://data.cimple...sPoliticalLeaning
http://data.cimple...logy#hasSentiment
http://data.cimple...readability_score
http://data.cimple...tology#hasEmotion
Faceted Search & Find service v1.16.115 as of Oct 09 2023


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data] Valid XHTML + RDFa
OpenLink Virtuoso version 07.20.3238 as of Jul 16 2024, on Linux (x86_64-pc-linux-musl), Single-Server Edition (126 GB total memory, 3 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software